<DOC>
	<DOCNO>NCT00064090</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy cytarabine use different way stop cancer cell divide stop grow die . 3-AP may stop growth cancer cell block enzymes necessary cancer cell growth may help cytarabine kill cancer cell make sensitive drug . PURPOSE : Phase I trial study effectiveness combine cytarabine 3-AP treating patient relapse refractory hematologic cancer .</brief_summary>
	<brief_title>3-AP Cytarabine Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility , tolerability , toxic effect 3-AP combination cytarabine patient hematologic malignancy . - Determine maximum tolerate dose phase II dose cytarabine regimen patient . - Determine biological effect 3-AP interaction cytarabine patient . OUTLINE : This pilot , dose-escalation study cytarabine . Patients receive 3-AP IV 6 hour follow cytarabine IV 18 hour day 1-5 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients achieve response may receive additional course consolidation therapy . Cohorts 3-6 patient receive escalate dos cytarabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional 10 patient receive treatment dose . PROJECTED ACCRUAL : Approximately 20-25 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow hematologic malignancy : Acute myeloid leukemia Acute lymphoblastic leukemia Chronic myelogenous leukemia ( CML ) CML blast crisis Chronic lymphocytic leukemia Highrisk* myelodysplastic syndrome , include follow : Refractory anemia excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia NOTE : *Highrisk myelodysplasia define International Performance Scoring System score least 1.5 , base adverse cytogenetics , great 10 % blast marrow , cytopenias least 2 lineage Relapsed refractory disease Ineligible high priority protocols PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy More 2 month Hematopoietic See Disease Characteristics Hepatic Bilirubin great 2.0 mg/dL ( unless consider due malignancy ) ALT AST great 3 time upper limit normal Chronic hepatitis allow Renal Creatinine great 2.0 mg/dL ( unless consider due malignancy ) Cardiovascular No myocardial infarction within past 3 month No symptomatic coronary artery disease No arrhythmia ( atrial fibrillation flutter ) require treatment No uncontrolled congestive heart failure Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Concurrent infection active treatment control antibiotic allow No concurrent lifethreatening illness No mental deficit psychiatric history would preclude give informed consent comply protocol PRIOR CONCURRENT THERAPY : Biologic therapy At least 1 week since prior growth factor , include follow : Epoetin alfa Filgrastim ( GCSF ) Sargramostim ( GMCSF ) Interleukin3 Interleukin11 No concurrent anticancer immunotherapy Chemotherapy At least 72 hour since prior hydroxyurea Recovered prior chemotherapy No concurrent anticancer chemotherapy Endocrine therapy Not specify Radiotherapy At least 2 week since prior radiotherapy No concurrent anticancer radiotherapy Surgery Not specify Other At least 3 week since prior myelosuppressive cytotoxic agent ( absence rapidly progress disease ) At least 1 week since prior nonmyelosuppressive therapy No concurrent standard investigational therapy malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>